<ul><li>Antiverse, a techbio company, has secured €4.2 million in seed funding to advance generative AI antibody design.</li><li>The funding round was led by i&i Biotech Fund I and Kadmos Capital, with contributions from existing investors.</li><li>Antiverse uses generative AI technology to design antibodies for challenging targets, such as G-protein-coupled receptors (GPCRs) and ion channels.</li><li>The funding will accelerate the development of Antiverse's AI-driven antibody platform and drive assets towards clinical trials.</li></ul>

Cardiff-based Antiverse secures €4.2 million to advance generative AI antibody design

Discover more